Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism and account for less than 2% of all pituitary adenomas. In the last years, the diagnosis has been facilitated by the routine use of ultra-sensitive TSH immunometric assays. Failure to recognise the presence of a TSHoma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumour volume to further expand. The diagnosis mainly rests on dynamic testing, such as T3 suppression tests and TRH, which are useful in differentiating TSHomas from the syndromes of thyroid hormone resistance. The first therapeutical approach to TSHomas is the pituitary neurosurgery. The medical treatment of TSHomas mainly rests on the administration of somatostatin analogues, such as octreotide and lanreotide, which are effective in reducing TSH secretion in more than 90% of patients with consequent normalisation of FT4 and FT3 levels and restoration of the euthyroid state.
Pituitary tumours : TSH-secreting adenomas / P. Beck Peccoz, L. Persani, D. Mannavola, I. Campi. - In: BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL ENDOCRINOLOGY & METABOLISM. - ISSN 1521-690X. - 23:5(2009), pp. 597-606.
|Titolo:||Pituitary tumours : TSH-secreting adenomas|
BECK PECCOZ, PAOLO LUIGI MARIA (Primo)
PERSANI, LUCA (Secondo)
CAMPI, IRENE (Ultimo)
|Parole Chiave:||pituitary glycoprotein hormone α-subunit (α-GSU); resistance to thyroid hormones; somatostatin analogues (octreotide, lanreotide); thyroid hyperfunction; thyrotropin (thyroid-stimulating hormone, TSH); TSH-induced; TSH-secreting pituitary adenomas (TSHomas)|
|Settore Scientifico Disciplinare:||Settore MED/13 - Endocrinologia|
|Data di pubblicazione:||2009|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.beem.2009.05.006|
|Appare nelle tipologie:||01 - Articolo su periodico|